Arctic Bioscience – Board approval of share capital increase related to conversion of debt

Arctic Bioscience’s board approved a share capital increase to NOK 2,695,625.60 through issuance of 96,916 new shares (nominal NOK 0.10) at NOK 2.789659405 per share, raising NOK 270,362.63 in total and NOK 260,671.03 to share premium as part of a debt conversion announced 9 December 2025; following registration the company will have 26,956,256 shares outstanding. The transaction represents a modest equity issuance (about 0.36% dilution), slightly strengthens the balance sheet by converting debt to equity and brings limited immediate cash/credit relief, and is unlikely to materially affect market capitalization; Arctic Bioscience remains focused on development of HRO350 for mild-to-moderate psoriasis and its ROMEGA® nutraceutical business.

Analysis

Arctic Bioscience's board on 12 December 2025 resolved to increase share capital from NOK 2,685,934 to NOK 2,695,625.60 by issuing 96,916 new shares at a subscription price of NOK 2.789659405 per share, producing a total subscription amount of NOK 270,362.63 and a share premium of NOK 260,671.03. Following registration the company will have 26,956,256 shares outstanding. The action was executed under an authorization from the 26 May 2025 general meeting and follows the company's 9 December 2025 notice regarding conversion of debt to equity.

The issuance is a debt-conversion transaction rather than a large primary cash raise, reducing liabilities and increasing equity via the recorded share premium. The new shares represent roughly 0.36% dilution, so immediate market-cap and ownership impacts are immaterial; the article and signals indicate neutral market sentiment and very low market-impact (score ~0.05). The absolute amounts involved (NOK ~270k) are small relative to typical biotech financing needs, so this is unlikely to materially change funding runway.

Operationally, Arctic remains focused on development of HRO350 for mild-to-moderate psoriasis and sales of ROMEGA® nutraceuticals; the capital move modestly improves the balance sheet but does not advance programs. Investors should interpret the conversion as a pragmatic liability-management step and watch for larger financing or clinical-readout catalysts that would meaningfully affect valuation and dilution.

Key Decisions for Investors

• Treat the capital increase as neutral in magnitude and maintain current positions while awaiting clinical or commercial catalysts for HRO350 and ROMEGA,
• Monitor forthcoming regulatory filings and company announcements for any additional debt conversions or larger equity raises that would produce material dilution or change the funding runway,
• If exposure is significant, consider sizing positions conservatively or employing hedges until the company provides clearer financing details or key clinical readouts